HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women

Duvlis, Sotirija; Popovska-Jankovic, Katerina; Arsova, Zorica Sarafinovska; Memeti, Shaban; Popeska, Zaneta; Plaseska‐Karanfilska, Dijana

doi:10.1002/jmv.24199

Cited by 40 publications

(27 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, for patients with low-grade lesions, HPV DNA testing gave a higher rate of positive results compared to the HR-HPV RT-qDx assay (39.2% vs. 25.9%). These results are similar to those of a previous study that compared the performance of the NucliSENS Easy Q HPV test (bioMérieux) and HPV-HR genotyping multiplex real-time PCR test (Sacace) in clinical specimens (Duvlis et al, 2015). These results suggest that the selective targeting used in the HR-HPV E6/E7 mRNA assay can reduce the positive detection rate of HPV infections in women with normal or low-grade lesions.…”

Section: Discussionsupporting

confidence: 88%

Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening

Wang¹,

Kim

Park

2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Pap smear and high-risk human papillomavirus (HR-HPV) DNA testing are the most widely applied methods for cervical cancer screening, but both methods are limited by their low specificity and lack of association with patient prognoses. The aim of this study was to compare the clinical and prognostic significance of HPV E6/E7 mRNA as an early biomarker with cytology and HPV DNA detection in cervical cancer screening. Methods: This study evaluated the performance of the Optimygene HR-HPV RT-qDx assay, which is an HPV E6/E7 mRNA-based assay, to detect 16 HR-HPV subtypes:

show abstract

Section: Discussionsupporting

confidence: 88%

Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening

Wang¹,

Kim

Park

2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…In comparison, the specificity of HR HPV DNA test was equal to 18%. What is more, the authors emphasise the fact that the introduction of modern molecular diagnostics may significantly decrease the number of surgical procedures, and thus lower the costs associated with colposcopic examinations and cervical biopsies [23].…”

Section: Discussionmentioning

confidence: 99%

Sensitivity and specificity of hr hPV E6/E7 mrna test in detecting cervical squamous intraepithelial lesion and cervical cancer

Pruski

Przybylski

Lewek³

et al. 2019

Ginekol Pol

View full text Add to dashboard Cite

Objectives: The paper assess the relevance of HR HPV E6/E7 mRNA test in women with abnormal Pap results. Material and methods: Between 2013-2014, 125 women were subjects to the enhanced diagnostics due to abnormal Pap results. According to The Bethesda system, if ASC-US, AGC, LSIL, ASC-H, HSIL or cancer cells were present, the result was abnormal. The patients underwent the enhanced diagnostics which included the following procedures: Pap smear collection for molecular assessment of HR HPV E6/E7 mRNA test, the colposcopic examination and biopsy of clinically suspicious areas. Results: High-grade squamous intraepithelial lesions constituted the most frequent cervical pathology in women with abnormal Pap test results, as well as with the positive results of HR HPV E6/E7 mRNA test. Test sensitivity in patients with the histopathological diagnosis of high-grade squamous intraepithelial lesion was estimated at 86.1%. Conclusions: HR HPV E6/E7 mRNA test identifying neoplastic lesions and cervical cancer is characterised by a high relevance which is reflected by means of sensitivity and specificity. In fact, test sensitivity and specificity increased with the age in the group of patients up to 50 years old.

show abstract

“…This results in a higher positive predictive value than DNA tests as to the viral carcinogenic activity. Several studies have shown that these tests may be clinically useful because of their higher specificity for detecting cervical disease [30][31][32].…”

Section: Discussionmentioning

confidence: 99%

Detection of E6/E7 human papilloma virus (HPV) transcripts in lymph nodes of patients with cervical cancer

Basiletti¹,

Soderini²,

Picconi³

et al. 2017

Integr Cancer Sci Therap

View full text Add to dashboard Cite

Volume 4(5): [1][2][3][4][5] types that taxonomically correspond to A7 (HPV 18, 39, 45, 59 and 68) and A9 species (HPV 16,31, 33, 35, 52 and 58) Hospital Nacional "Profesor Alejandro Posadas", Argentina 5Hospital Municipal "Juan A. Fernández", Argentina AbstractPersistent high risk Human Papillomavirus (HPV) infection is necessary for the development of cervical cancer (CC). HPV carcinogenesis is based on viral E6 and E7 proteins' capacity to interfere in cell proliferation control. The metastasis status of pelvic lymph nodes (PLN) is a critical parameter in post-operative decisions on adjuvant therapy, given its strong correlation with recurrence in CC. In order to complement the histopathological evaluation of subclinical node metastases, we evaluated the application of a commercial HPV E6 / E7 mRNA kit, to detect viral messenger RNAs in lymph nodes and tumors of patients with CC.Forty five cervical primary tumors and 152 PLN ( 3-4 from each patient) were included. HPVs were typed in tumors by PCR (polymerase chain reaction) using generic primers PGMY and reverse line blot hybridization (RLB) with type-specific oligo probes corresponding to 37 HPV types that infect the anogenital tract. PNL were collected in RNAlater (Invitrogen) and mRNA was extracted using the MiniMag (Biomerieux) system. Detection of E6 and E7 mRNAs corresponding to HPVs types 16, 18, 31, 33 and 45 was carried out using isothermal real time PCR (NucliSENS EasyQ HPV, Biomerieux).HPV was detected in the tumors of 42 patients; the viral types identified were HPV16 (n = 32), HPV18 (n = 5), HPV31 (n = 3), HPV45 (n = 2), HPV59 (n = 1) and HPV73 (n = 1). These last 2 cases were not considered in the study because the mRNA detection system does not include these viral types. Also excluded were 2 cases whose tumors were HPV negative. There was a high correlation between the histological and virological results. Seventy-two percent of the histologically positive PLN were positive for E6-E7 mRNA; while 93% (125/134) of the negative PLN were also negative for E6-E7 mRNA assay. There was, however 8% (9/134) of negative PLN in which viral messengers were detected.Patients' follow up was limited (4 years) and except for two patients who died (both positive for HPV 45) in the period under review, no recurrences were recorded in any of the patients included in the study.The presence of HPV in PLN may indicate a metastasis, as since the virus is not able of producing viremia or invading tissues it can only be "transported" by the cancer cell. The presence of HPV mRNA indicates viral genome transcription, a process which occurs in a lymph node only in CC metastatic cells, as these viruses can only replicate in epithelial-origin cells. Therefore, the findings of these mRNAs in the negative pelvic lymph nodes point out a very early metastasis, detectable at molecular level, but unobservable on histological diagnosis.The commercial kits for HPV E6/E7 mRNA detection, usually applied for the cervical disease management, may be used also to evaluate PLN biopsie...

show abstract

HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women

Cited by 40 publications

References 57 publications

Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening

Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening

Sensitivity and specificity of hr hPV E6/E7 mrna test in detecting cervical squamous intraepithelial lesion and cervical cancer

Detection of E6/E7 human papilloma virus (HPV) transcripts in lymph nodes of patients with cervical cancer

Contact Info

Product

Resources

About